CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Eltrombopag olamine

Last Updated: April 26, 2011
Result type: Reports
Project Number: SR0230-000
Product Line: Reimbursement Review

Generic Name: Eltrombopag olamine

Brand Name: Revolade

Manufacturer: GlaxoSmithKline

Therapeutic Area: Chronic immune thrombocytopenic purpura

Indications: Thrombocytopenic purpura chronic immune (idiopathic)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 24, 2011

Recommendation Type: Do not list